Skip to main content

Table 1 Effect of 3,6-dihydroxyflavone on cancer endpoints and body weight

From: MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis

Group

Total number of rats

Number of rats with tumor

Incidence (%)

Multiplicity (average number/rat)

Latency (days)

Final body weight (g)

No treatment

8

0

0

-

-

291.3 ± 5.2

MNU only

14

13

92.8

2.6 ± 0.6

74.4 ± 7.1

281.7 ± 4.8

MNU + 10 mg/kg 3,6-DHF

14

9

64.3

2.2 ± 0.3

80.8 ± 7.8

275.5 ± 5.8

MNU + 20 mg/kg 3,6-DHF

14

8*

57.1*

1.9 ± 0.4*

87.5 ± 5.1**

278.7 ± 5.1

  1. Data presented as mean ± standard deviation. *P < 0.05, **P < 0.01 compared with the 1-methyl-1-nitrosourea (MNU)-only treatment group. Tumor incidence in the MNU + 20 mg/kg 3,6-dihydroxyflavone (3,6-DHF) treatment group was significantly lower than that in the MNU-only treatment group, indicating that oral administration of 3,6-DHF (20 mg/kg/day) can effectively suppress MUN-induced mammal carcinogenesis.